AstraZeneca is paying Sino Biopharmaceutical $200 million upfront for ex-China rights to a late-phase challenger to Merck & Co.’s chronic obstructive pulmonary disease drug Ohtuvayre.
Source: FierceBiotech
You may also like
SMC recommends VEOZA for moderate to severe menopausal...
SMC backs Columvi combination for second-line lymphoma...
Bristol Myers Squibb’s New Drug Application for...
Exonate appoints Olav Hellebø as CEO
Immune Evasion Uncovered by Virome-Wide Ubiquitin...
Genetic Map Opens Door to Development of New Therapies...
About the author
David Miller
a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.